API | pemigatinib

pemigatinib (Pemazyre) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Breakthrough Therapy ^FDA Accelerated Approval ^FDA Priority Review ^FDA

AACT

Active Ingredient History

NOW

Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading. ^Wikipedia

Chemistry

SMILES: CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21
InChIKey: HCDMJFOHIXMBOV-UHFFFAOYSA-N
Mol. Mass: 487.51
ALogP: 3.66 Partition coefficient
ChEMBL Molecule:
pemigatinib

More Chemistry

Pharmacology

Mechanisms of Action:
- Fibroblast growth factor receptor 1 (Homo sapiens) ^UniProt
- Fibroblast growth factor receptor 2 (Homo sapiens) ^UniProt
- Fibroblast growth factor receptor 2 (Homo sapiens) ^UniProt
- Fibroblast growth factor receptor 3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Drug Pricing (per unit)

United States

$908.9450 - $1195.9800

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

incb054828

Organizations (28)

Research & Development (28)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (27)

Approved Indications (2)

Bile Duct Neoplasms

Cholangiocarcinoma

Experimental Indications - Clinical Trial Phases 1-4 (26)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 3)

Colitis, Ulcerative (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 2)

Digestive System Neoplasms (Phase 2)

Drug Therapy (Phase 1/Phase 2)

Endometrial Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Immune Checkpoint Inhibitors (Phase 2)

Leukemia, Myeloid, Acute (Phase 1)

Lung Neoplasms (Phase 1/Phase 2)

Lymphoma (Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Mutation (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Receptors, Fibroblast Growth Factor (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 36
# of Trial Organizations: 28

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue